Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB27A | P51159 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475034 | 1.00 | AURKA (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1655345 | 0.94 | LCK (0.40) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1655756 | 0.94 | AURKA (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL29475077 | 0.94 | AURKA (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1655324 | 0.93 | AURKA (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1655528 | 0.93 | PIK3CD (0.40) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL29475081 | 0.93 | AURKA (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL22196779 | 0.92 | LCK (0.39) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16892894 | 0.91 | PIK3CD (0.35) | AURKAAURKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1655336 | 0.91 | BRAF (0.33) | LCKBRAFMAPTABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | claimed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | claimed |
| EP-2983669-B1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS | Bayer Pharma AG (DE) | 2018-10-24 | — | — | EP | claimed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | claimed |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-15 | — | — | US | claimed |
| EP-3268005-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-17 | — | — | EP | claimed |
| US-20160303136-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | claimed |
| WO-2016142313-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | WO | claimed |
| US-20160058770-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-03 | — | — | US | claimed |
| EP-2096919-B1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | claimed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | claimed |
| EP-2344164-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-07-20 | — | — | EP | claimed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | claimed |
| WO-2010034414-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-2168582-A1 | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2168583-A1 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2096919-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | claimed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | AURKA 781/4885AURKB 763/4885PIK3CD 2/4885 |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | AURKA 86/4885AURKB 51/4885PIK3CD 2/4885 |
| US-20160058770-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS | BCL6B, BCL9, BCL9L | AURKA 692/4885AURKB 68/4885PIK3CD 444/4885 |
| US-20180042929-A1 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | PIK3R4, PIK3R5, PIK3C2B | AURKA 207/4885AURKB 178/4885PIK3CD 9/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | AURKA 1456/4885AURKB 542/4885PIK3CD 32/4885 |
| US-20160303136-A1 | COMBINATION OF PI3K-INHIBITORS | PIK3CA, AKT3, AKT2 | AURKA 1574/4885AURKB 889/4885PIK3CD 4/4885 |
| US-20110251191-A1 | USE OF SUBSTITUTED 2, 3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR THE TREATMENT OF MYELOMA | MCL1, BCL9, BCL3 | AURKA 1168/4885AURKB 1260/4885PIK3CD 1037/4885 |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | PIK3CA, PIK3CD, PIK3CB | AURKA 781/4885AURKB 763/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.